Fate Therapeutics (FATE) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, with a pipeline including off-the-shelf, multiplexed-engineered T-cell and NK-cell product candidates and ongoing collaborations, notably with Ono Pharmaceutical.

• Initiation of RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis planned for H2 2026, with unique, less-intensive conditioning and on-demand product availability.

• FT819 selected for FDA's CDRP program, enhancing regulatory engagement and potentially accelerating registration pathway.

• Clinical data for FT819 show meaningful and durable responses in SLE, with improved safety and quality of life, including outpatient treatment feasibility.

• Next-generation CAR T-cell programs FT839 and FT836 advancing, with FT839 IND submission planned and FT836 showing favorable safety in early trials.

Financial highlights

• Collaboration revenue was $1.3 million, down from $1.6 million year-over-year, primarily from research and preclinical development services with Ono Pharmaceutical.

• Research and development expenses decreased to $24.7 million from $29.1 million, and general and administrative expenses fell to $9.6 million from $13.8 million, mainly due to lower employee and stock-based compensation.

• Total operating expenses for Q1 2026 were $34.3 million, down 20% year-over-year.

• Net loss for Q1 2026 was $31.2 million, compared to $37.6 million in the prior year quarter.

• Cash, cash equivalents, and short-term investments totaled $174.8 million as of March 31, 2026, expected to fund operations for at least the next twelve months and extend runway into 2028.

Outlook and guidance

• Management expects continued significant operating losses as research, development, and manufacturing activities persist.

• Sufficient funding is projected for at least the next twelve months, with runway extended into 2028, but additional capital will be required for long-term operations and product development.

• Enrollment for RECLAIM-LN expected to complete within 15 months of trial initiation.

• Further clinical updates anticipated at major scientific conferences in 2026.